Taysha Gene Therapies (TSHA) Competitors $2.89 -0.04 (-1.37%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.85 -0.04 (-1.38%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. RXRX, TARS, BEAM, APGE, SDGR, CNTA, BHC, ARQT, AGIO, and GLPGShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Schrödinger (SDGR), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Taysha Gene Therapies vs. Recursion Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Apogee Therapeutics Schrödinger Centessa Pharmaceuticals Bausch Health Companies Arcutis Biotherapeutics Agios Pharmaceuticals Galapagos Taysha Gene Therapies (NASDAQ:TSHA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Do analysts prefer TSHA or RXRX? Taysha Gene Therapies currently has a consensus price target of $6.57, indicating a potential upside of 127.39%. Recursion Pharmaceuticals has a consensus price target of $7.60, indicating a potential upside of 85.82%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to TSHA or RXRX? In the previous week, Taysha Gene Therapies had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Taysha Gene Therapies and 6 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 1.24 beat Taysha Gene Therapies' score of 0.76 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TSHA or RXRX? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 2.7% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TSHA or RXRX more profitable? Taysha Gene Therapies has a net margin of -229.67% compared to Recursion Pharmaceuticals' net margin of -579.52%. Recursion Pharmaceuticals' return on equity of -76.56% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Recursion Pharmaceuticals -579.52%-76.56%-55.68% Does the MarketBeat Community believe in TSHA or RXRX? Taysha Gene Therapies received 79 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 78.17% of users gave Taysha Gene Therapies an outperform vote while only 56.14% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes11178.17% Underperform Votes3121.83% Recursion PharmaceuticalsOutperform Votes3256.14% Underperform Votes2543.86% Which has more volatility and risk, TSHA or RXRX? Taysha Gene Therapies has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Which has stronger valuation & earnings, TSHA or RXRX? Taysha Gene Therapies has higher earnings, but lower revenue than Recursion Pharmaceuticals. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M71.12-$111.57M-$0.34-8.50Recursion Pharmaceuticals$59.82M27.80-$328.07M-$1.77-2.31 SummaryTaysha Gene Therapies beats Recursion Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$592.61M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio4.5930.5026.8419.71Price / Sales71.12400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book7.233.286.794.50Net Income-$111.57M-$72.17M$3.23B$248.18M7 Day Performance12.89%2.96%1.53%0.20%1 Month Performance62.36%3.25%10.06%12.37%1 Year Performance-2.69%-28.29%16.72%7.04% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies2.8669 of 5 stars$2.89-1.4%$6.57+127.4%+0.0%$592.61M$8.33M4.59180Earnings ReportAnalyst RevisionGap DownRXRXRecursion Pharmaceuticals2.4162 of 5 stars$4.64+7.2%$7.60+63.8%-57.0%$1.87B$59.82M-3.03400Positive NewsGap DownTARSTarsus Pharmaceuticals3.273 of 5 stars$44.20-1.3%$66.33+50.1%+14.2%$1.86B$233.67M-11.6050Positive NewsBEAMBeam Therapeutics3.1284 of 5 stars$18.24+4.8%$48.75+167.3%-30.6%$1.83B$63.58M-10.36510Positive NewsAPGEApogee Therapeutics2.1522 of 5 stars$39.58+6.1%$94.60+139.0%-18.3%$1.78BN/A-16.3691Positive NewsGap DownSDGRSchrödinger2.9482 of 5 stars$24.17+1.1%$32.80+35.7%-6.9%$1.77B$207.54M-10.33790Positive NewsCNTACentessa Pharmaceuticals3.5466 of 5 stars$13.15+6.9%$27.00+105.3%+49.1%$1.75B$6.85M-8.59200Positive NewsInsider TradeAnalyst RevisionGap UpBHCBausch Health Companies4.1641 of 5 stars$4.79+4.2%$7.42+55.0%-31.3%$1.73B$9.73B-39.8719,900Gap UpARQTArcutis Biotherapeutics2.7689 of 5 stars$14.39+6.4%$18.80+30.6%+45.1%$1.72B$212.82M-8.04150News CoveragePositive NewsInsider TradeAGIOAgios Pharmaceuticals3.9879 of 5 stars$29.14+6.7%$56.00+92.2%-11.1%$1.69B$37.04M2.57390Positive NewsAnalyst DowngradeGLPGGalapagos0.4742 of 5 stars$25.07-1.0%$25.33+1.1%+2.1%$1.65B$288.19M0.001,310Positive News Related Companies and Tools Related Companies RXRX Alternatives TARS Alternatives BEAM Alternatives APGE Alternatives SDGR Alternatives CNTA Alternatives BHC Alternatives ARQT Alternatives AGIO Alternatives GLPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
